Arena, Eisai deal

Arena amended its licensing agreement with Eisai, granting the Japanese pharma worldwide development and commercialization rights to obesity drug Belviq lorcaserin. Eisai

Read the full 223 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE